Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer
C. Benvenuti, Rita De Sanctis(Humanitas University), Jean Zeghondy(Institut Gustave Roussy), Meriem Mokdad-Adi(Institut Gustave Roussy), Mariangela Gaudio(Humanitas University), Caroline Poisson(Université Paris-Saclay), Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Saltalamacchia, Jacopo Canzian(Humanitas University), Alessandro Viansone(Institut Gustave Roussy), Alberto Zambelli(Ospedale Papa Giovanni XXIII), Riccardo Gerosa(Humanitas University), Laura Clapis(Humanitas University), Barbara Pistilli(Institut Gustave Roussy), Armando Santoro(IRCCS Humanitas Research Hospital), Thomas Grinda(Institut Gustave Roussy)
Cited by 0
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Challenges in Using Circulating miRNAs as Cancer Biomarkers
|BioMed Research International|2015|264
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
|The Lancet Oncology|2019|195
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178